Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia. Pediatr Infect Dis J 2009 May;28(5):445-7

Date

03/20/2009

Pubmed ID

19295462

DOI

10.1097/INF.0b013e3181927891

Scopus ID

2-s2.0-67649531477 (requires institutional sign-in at Scopus site)   16 Citations

Abstract

Daptomycin is a Food and Drug Administration-approved alternative to vancomycin for the treatment of serious methicillin-resistant Staphylococcus aureus infections in adults. Treatment failure with daptomycin is increasingly reported in adults, but data in children are limited. We report an adolescent patient with severe burn injuries who had persistent methicillin-resistant Staphylococcus aureus bacteremia and rapidly developed nonsusceptibility to daptomycin. We review the relevant literature.

Author List

Jacobson LM, Milstone AM, Zenilman J, Carroll KC, Arav-Boger R

Author

Ravit Boger MD Chief, Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adolescent
Anti-Bacterial Agents
Bacteremia
Daptomycin
Drug Therapy, Combination
Gentamicins
Humans
Male
Methicillin-Resistant Staphylococcus aureus
Microbial Sensitivity Tests
Staphylococcal Infections
Vancomycin